REM1
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
16/02/2026
Voltar para busca
Dado oficial do USPTO
NOURIN
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
22
Atualização mais recente
17/02/2026
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
1, 5
Data de depósito
21/01/2020
Data de registro
16/02/2021
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
16/02/2021
Última transação
17/02/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Fundamento do pedido
Intent to use
Primeiro uso
19/10/2020
Primeiro uso no comércio
19/10/2020
Código do desenho
4
Tipo de titular
03
Localização do titular
Vienna, VA
Examinador
MAYES, LAURIE ANN
Unidade examinadora
L10
Localização atual
PUBLICATION AND ISSUE SECTION
Titulares e representantes
Titulares
Nour Heart, Inc.
Representantes
Shuo Che Chou SINORICA LLC DBA THOUGHTS TO PAPER
Classificação técnica
Classes Nice
Classe 1Classe 5
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 1
protein arrays for research purposes; gene-based RNA molecular network being RNA sequences for research purposes; protein arrays for diagnosing of heart-related diseases anginaheart attackcardiac and non-cardiac chest painheart failurecardiovascular diseasesacute coronary syndromescoronary artery diseaseischemic cardiac diseasesubclinical or silent ischemialow-grade myocardial ischemiaheart transplantation for cardiac allograft inflammationmonitor disease progressionseverity of heart damagerisk assessment and prognosisdisease progressionmyocardial cell damagepatients at-risk for coronary artery diseasepredict drug therapy response on heart tissue (myocardial cell damage) in clinical trials as well as other diseasesall of the foregoing for research purposes; gene-based RNA molecular network being RNA sequences for diagnosing of heart-related diseases anginaheart attackcardiac and non-cardiac chest painheart failurecardiovascular diseasesacute coronary syndromescoronary artery diseaseischemic cardiac diseasesubclinical or silent ischemialow-grade myocardial ischemiaheart transplantation for cardiac allograft inflammationmonitor disease progressionseverity of heart damagerisk assessment and prognosisdisease progressionmyocardial cell damagepatients at-risk for coronary artery diseasepredict drug therapy response on heart tissue (myocardial cell damage) in clinical trials as well as other diseasesall of the foregoing for research use; diagnostic biomarker reagents for research purposes; protein arrays of biomarker reagents for research purposes; gene-based RNA molecular network biomarker reagents for research purposes; protein arrays and gene-based RNA molecular network biomarker reagents for research purposes; tissue-derived diagnostic biomarker reagents for research purposes; cardiac-derived diagnostic biomarker reagents for research purposes
Classe 5
protein arrays for medical diagnosis purposes; gene-based RNA molecular network being RNA sequences for medical diagnosis purposes; protein arrays for diagnosing of heart-related diseases anginaheart attackcardiac and non-cardiac chest painheart failurecardiovascular diseasesacute coronary syndromescoronary artery diseaseischemic cardiac diseasesubclinical or silent ischemialow-grade myocardial ischemiaheart transplantation for cardiac allograft inflammationmonitor disease progressionseverity of heart damagerisk assessment and prognosisdisease progressionmyocardial cell damagepatients at-risk for coronary artery diseasepredict drug therapy response on heart tissue (myocardial cell damage) in clinical trials as well as other diseasesall of the foregoing for medical diagnosis purposes; gene-based RNA molecular network being RNA sequences for diagnosing of heart-related diseases anginaheart attackcardiac and non-cardiac chest painheart failurecardiovascular diseasesacute coronary syndromescoronary artery diseaseischemic cardiac diseasesubclinical or silent ischemialow-grade myocardial ischemiaheart transplantation for cardiac allograft inflammationmonitor disease progressionseverity of heart damagerisk assessment and prognosisdisease progressionmyocardial cell damagepatients at-risk for coronary artery diseasepredict drug therapy response on heart tissue (myocardial cell damage) in clinical trials as well as other diseasesall of the foregoing for medical use; diagnostic biomarker reagents for medical purposes; protein arrays of biomarker reagents for medical diagnosis purposes; gene-based RNA molecular network biomarker reagents for medical diagnosis purposes; protein arrays and gene-based RNA molecular network biomarker reagents for medical diagnosis purposes; tissue-derived diagnostic biomarker reagents for medical purposes; cardiac-derived diagnostic biomarker reagents for medical purposes
Publicações
Histórico de despachos e eventos da marca no USPTO.
22 publicações encontradas
R.PR
REGISTERED-PRINCIPAL REGISTER
16/02/2021
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
15/01/2021
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
14/01/2021
SUPC
STATEMENT OF USE PROCESSING COMPLETE
14/01/2021
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
13/01/2021
IUAF
USE AMENDMENT FILED
22/12/2020
EISU
TEAS STATEMENT OF USE RECEIVED
22/12/2020
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
04/08/2020
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
09/06/2020
PUBO
PUBLISHED FOR OPPOSITION
09/06/2020
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
20/05/2020
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
05/05/2020
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
25/04/2020
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
24/04/2020
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
24/04/2020
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
13/04/2020
GNRT
NON-FINAL ACTION E-MAILED
13/04/2020
CNRT
NON-FINAL ACTION WRITTEN
13/04/2020
DOCK
ASSIGNED TO EXAMINER
08/04/2020
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
25/01/2020
NWAP
NEW APPLICATION ENTERED
24/01/2020
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace NOURIN ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.